Compare Enveric Biosciences Inc (ENVB) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs STMicroelectronics NV — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while STMicroelectronics NV trades at $53.44 (market cap $50.29B). The key difference: STMicroelectronics NV is far larger — about 7517.2× Enveric Biosciences Inc's market cap, and STMicroelectronics NV pays a 0.64% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and STMicroelectronics NV for 66 Days on average.
| ENVB | STM | |
|---|---|---|
Market Cap | $6.69M | $50.29B |
Volume | 41,141 | 9,536,788 |
Sector | Health | Technology |
52-Week High | $10.80 | $79.91 |
52-Week Low | $1.27 | $21.20 |
Typical Hold Time | 14 Days | 66 Days |
Enterprise Value | -$1.60M | $47.81B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
STM (STMicroelectronics) trades at $52.71, down 10.24% in the last session. The stock shows a bullish technical signal with moving averages supporting an uptrend, though oscillators are neutral. Fundamentally, revenue declined to $11.80B in 2025 with a net income margin of -0.39%, but recent Q2 2026 earnings beat expectations. Analyst sentiment is positive with a consensus price target of $77.31. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2B by 2027.
The outlook for STM hinges on execution in AI and automotive segments, offering growth potential, but risks include margin pressures from fab transitions and competitive threats. Wall Street's buy rating majority (51.72%) reflects optimism, though investors should monitor earnings consistency and debt levels, with the stock trading below consensus target indicating potential upside if recovery sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
